Envoy Medical Submits First Module of Modular Premarket Approval Application to the U.S. Food and Drug Administration for Breakthrough-Designated Device
Rhea-AI Summary
Envoy Medical (NASDAQ: COCH) submitted the first module of its modular Premarket Approval (PMA) application to the FDA for its Breakthrough Device-designated Acclaim cochlear implant. The plan includes four modules, with the final clinical module targeted for Q2 2027, supporting ongoing FDA interaction and clearer investor milestones.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- First module of modular PMA application submitted to FDA for Acclaim
- Plan for four PMA modules with defined regulatory milestones
- Final clinical data module targeted for submission in Q2 2027
- Device holds FDA Breakthrough Device Designation since 2019
- Acclaim cochlear implant is in a U.S.-based pivotal clinical trial
- Modular PMA enables earlier and ongoing FDA engagement and feedback
Negative
- Regulatory process extends to at least Q2 2027 for final clinical module
- Only the first of four PMA modules has been submitted; approval risk remains
- Pivotal clinical trial is still ongoing, so final efficacy and safety data are pending
News Market Reaction – COCH
On the day this news was published, COCH gained 15.96%, reflecting a significant positive market reaction. Argus tracked a peak move of +30.4% during that session. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $9M to the company's valuation, bringing the market cap to $65.34M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 25 | ATM facility termination | Positive | +6.7% | Termination of $15M ATM equity facility citing confidence in capital position. |
| Jun 18 | Investor conferences | Neutral | -0.7% | CEO scheduled to present at two investor-focused virtual conference events. |
| Jun 04 | Conference presentation | Neutral | +1.8% | Planned presentation at Planet MicroCap Conference Las Vegas with webcast access. |
| May 20 | Patent portfolio expansion | Positive | -0.1% | Announcement of multiple new patents for fully implanted hearing technologies. |
| May 11 | Milestones & Q1 update | Positive | -0.2% | Q1 results plus pivotal trial progress and PMA advancement for Acclaim implant. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often triggers modest moves, with some positive regulatory and IP milestones seeing muted or slightly negative price reactions.
Key Terms
modular premarket approval regulatory
pma regulatory
breakthrough device designation regulatory
pivotal clinical trial medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Modular Regulatory Strategy Creates Defined Milestone Cadence, Enables Earlier FDA Engagement, and Supports Targeted Final Clinical Module Submission Planned for Q2 2027
White Bear Lake, Minnesota--(Newsfile Corp. - June 30, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the submission of the first module of its Modular Premarket Approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for its FDA Breakthrough Device-designated product.
The submission marks the first regulatory milestone in the Company's planned modular PMA strategy. Unlike a traditional PMA, which is submitted as a single comprehensive application, the modular PMA pathway allows the Company to submit completed sections to the FDA for review as they become available, rather than waiting to compile and submit the entire submission at once. Envoy Medical expects to submit a total of four modules, with the final module containing final clinical trial data targeted for submission in the second quarter of 2027.
By utilizing the modular PMA pathway, the Company expects to engage with the FDA throughout the review process, allowing for earlier regulatory feedback while establishing a series of defined development milestones. Management believes this approach provides investors with greater visibility into the Company's progress and may reduce execution risk by identifying potential issues earlier in the review process.
"We believe the modular PMA approach is the right strategy for advancing our breakthrough-designated device through the FDA review process," said Brent Lucas, Chief Executive Officer of Envoy Medical." This submission represents the first of several milestones that we expect to achieve over the coming quarters. Rather than concentrating regulatory risk into a single binary event at the end of a multi-year process, this approach gives us a roadmap with meaningful accomplishments along the way. Each submitted module enables ongoing engagement with the FDA and creates a clearer framework for measuring our execution. We remain focused on advancing what we believe is a differentiated hearing solution for a large population of people interested in Invisible Hearing® technology."
Key advantages of the modular PMA approach for Envoy Medical include:
Earlier FDA Engagement: The FDA can begin reviewing submitted modules, such as nonclinical data and manufacturing information, while the clinical trial is ongoing, allowing the review process to progress in parallel with remaining data collection.
Iterative Feedback and Risk Reduction: Receiving FDA input on individual modules allows the Company to address any questions or concerns proactively, reducing the chance of unanticipated issues or delays upon final submission. The Company believes this proactive approach reflects prudent use of capital and helps to reduce the risk profile of the overall regulatory process.
A Structured Investor Roadmap: With four planned modules, Envoy Medical expects to have multiple opportunities to report meaningful progress to investors over the next year, providing investor visibility into the Company's advancement toward a potential approval decision.
Aligned with Breakthrough Device Designation: As an FDA-designated Breakthrough Device, Envoy Medical's product is eligible for more intensive FDA interaction and guidance throughout the review process. The modular PMA structure, which requires FDA agreement and alignment on the submission framework in advance, is a natural fit for this level of ongoing collaboration with the FDA.
The Acclaim® cochlear implant received Breakthrough Device Designation from the FDA in 2019 and is currently under investigation as part of a U.S. based pivotal clinical trial. For more information on the trial, visit www.envoymedical.com/acclaim-pivotal.
To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line.
About Envoy Medical, Inc.
Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.
About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.
CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operations; the ability to obtain additional patents and develop future products or product improvements; the ability to maintain compliance with Nasdaq rules and requirements; the timing and future outcome of its FDA pivotal trial; the ability to raise capital and the amount of capital required to complete the FDA pivotal trial and early commercialization; the Acclaim CI being the first to market fully implanted cochlear implant; the timing and results of activations, enrollments, follow-up visits, data, and clinical trials of the Acclaim CI; performance of the Acclaim CI during clinical trials, including improvement of patient outcomes over time after implant; and the participation or any changes or delays in participation of any subjects, institutions, or healthcare professionals in such trials; the safety, performance, and market acceptance of the Acclaim CI; the timing and results of the Acclaim CI's PMA submissions to the FDA, including modular submissions and related feedback; the size of Envoy Medical's addressable market, operational performance, future market conditions or economic performance and developments in the capital and credit markets; and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical's Class A Common Stock; changes in or removal of Envoy Medical's shares inclusion in any index; Envoy Medical's success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; the ability to engage competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical's suppliers, or disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical's key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Annual Report on Form 10-K filed by Envoy Medical on March 23, 2026, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical's good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.
Investor Contact:
Phil Carlson
KCSA Strategic Communications
O: 212.896.1233
E: Envoy@kcsa.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303387